XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)
$ in Thousands
3 Months Ended
Jul. 28, 2023
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Retained Earnings (Accumulated Deficit)   $ (1,524,134) $ (1,529,194)
Cash, Cash Equivalents, and Short-Term Investments   $ 276,200  
Number of Reportable Segments   1  
Commercialization Agreement With Neuraxpharm [Member]      
License and Collaboration Agreements, One-time, Non-refundable Payment $ 140,000 $ 119,700